The resorcylic acid lactone hypothemycin selectively inhibits the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cells

Biological and Pharmaceutical Bulletin

Volumn 33, Issue 2, 2010, Pages 168-173

  Fukazawa, Hidesuke ^a   Ikeda, Yoshimi ^a,b   Fukuyama, Mari ^a   Suzuki, Takeshi ^b   Hori, Hiroshi ^c   Okuda, Toru ^c   Uehara, Yoshimasa ^d  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c TAMAGAWA UNIVERSITY   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

Hypothemycin; Protein kinase; Resorcylic acid lactone; Signal transduction

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CYSTEINE; GROWTH FACTOR; HYPOTHEMYCIN; LACTONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PROTEIN KINASE D; PROTEIN KINASE D1; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; ENVIRONMENT; ENZYME ACTIVATION; ENZYME INACTIVATION; HUMAN; HUMAN CELL; KIDNEY CELL; MORPHOLOGY; NONHUMAN; PHENOTYPE; RAT;

ANIMALS; BUTADIENES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FLAVONOIDS; GROWTH INHIBITORS; HUMANS; KIDNEY; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRILES; PROTEIN KINASE INHIBITORS; RATS; ZEARALENONE;

EID: 76049089947     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.33.168     Document Type: Article

References (15)

1. Winssinger N., Barluenga S., Chem. Commun. (Camb.), 2007, 22-36 (2007).
2. Camacho R., Staruch M. J., DaSilva C., Koprak S., Sewell T., Salituro G., Dumont F. J., Immunopharmacology, 44, 255-265 (1999).
3. Sonoda H., Omi K., Hojo K., Nishida K., Omura S., Sugita K., Life Sci., 65, 381-394 (1999).
4. Tanaka H., Nishida K., Sugita K., Yoshioka T., Jpn. J. Cancer Res., 90, 1139-1145 (1999).
5. Dakas P. Y., Barluenga S., Totzke F., Zirrgiebel U., Winssinger N., Angew. Chem. Int. Ed. Engl., 46, 6899-6902 (2007).
6. Ninomiya-Tsuji J., Kajino T., Ono K., Ohtomo T., Matsumoto M., Shiina M., Mihara M., Tsuchiya M., Matsumoto K., J. Biol. Chem., 278, 18485-18490 (2003).
7. Williams D. H., Wilkinson S. E., Purton T., Lamont A., Flotow H., Murray E. J., Biochemistry, 37, 9579-9585 (1998).
8. Zhao A., Lee S. H., Mojena M., Jenkins R. G., Patrick D. R., Huber H. E., Goetz M. A., Hensens O. D., Zink D. L., Vilella D., Dombrowski A. W., Lingham R. B., Huang L., J. Antibiot. (Tokyo), 52, 1086-1094 (1999).
9. Schirmer A., Kennedy J., Murli S., Reid R., Santi D. V., Proc. Natl. Acad. Sci. U.S.A., 103, 4234-4239 (2006).
10. Fukazawa H., Uehara Y., Cancer Res., 60, 2104-2107 (2000).
11. Solit D. B., Garraway L. A., Pratilas C. A., Sawai A., Getz G., Basso A., Ye Q., Lobo J. M., She Y., Osman I., Golub T. R., Sebolt-Leopold J., Sellers W. R., Rosen N., Nature (London), 439, 358-362 (2006).
12. Fukazawa H., Mizuno S., Uehara Y., Anal. Biochem., 228, 83-90 (1995).
13. Wee J. L., Sundermann K., Licari P., Galazzo J., J. Nat. Prod., 69, 1456-1459 (2006).
14. Rawlins P., Mander T., Sadeghi R., Hill S., Gammon G., Foxwell B., Wrigley S., Moore M., Int. J. Immunopharmacol., 21, 799-814 (1999).
15. Jensen B. M., Beaven M. A., Iwaki S., Metcalfe D. D., Gilfillan A. M., J. Pharmacol. Exp. Ther., 324, 128-138 (2008).